Compare Xylem, Inc. (XYL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Xylem, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Xylem, Inc. trades at $107.96 (market cap $25.41B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays the higher dividend (1.58%). Which is the better fit depends on your goals.
| XYL | ZBH | |
|---|---|---|
Market Cap | $25.41B | $17.97B |
Sector | Industrials | Health |
52-Week High | $152.95 | $104.26 |
52-Week Low | $105.69 | $79.58 |
Enterprise Value | $27.18B | $25.04B |
Dividend Yield | 1.58% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Xylem (XYL) trades at $108.81, up 2.95% in the last session, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.46 exceeding expectations. Revenue growth has been steady, rising from $5.5B in 2022 to $9.0B in 2025, while net income margins improved to 10.59%. Recent corporate actions include a dividend declaration and strategic acquisitions to bolster its industrial presence.
The outlook for XYL is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Upside potential is supported by a consensus price target of $152.29, implying significant appreciation. Risks include execution of recent acquisitions and macroeconomic pressures on industrial demand. The stock presents a compelling opportunity for long-term investors focused on water infrastructure growth.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
